Imaging of Brain Amyloid Plaques in the Aging Population
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to ascertain the relationship between change in amyloid burden over time, and concurrent change in clinical status.
Full description
Identification of risk factors and biomarkers of neurodegenerative disease is essential in caring for the growing numbers of elderly. Imaging biomarkers provide non-invasive ways to look at brain function. A new PET imaging agent, Pittsburgh Compound B (PiB), that identifies brain amyloid is an exciting development in brain imaging that needs to be studied. We plan to study this imaging technique in normal volunteers and patients with a variety of neurodegenerative diseases to determine its utility. Long term followup of these subjects will allow us to understand the predictive ability of this new test.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age 30-100
- Subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the Mayo Clinic Study of Aging, Mayo ADRC, or Mayo neurodegenerative disease clinics.
Exclusion criteria
- Subjects unable to lie down without moving for 10 minutes
- Women who are pregnant or cannot stop breast feeding for 24 hours at the time of scanning
- Claustrophobic patients unable to tolerate the scans
- Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc.
Trial design
Primary purpose
Allocation
Interventional model
Masking
8,000 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal